Does your IPF drug truly impact disease biology?

Extracellular matrix (ECM) remodeling is a central driver of disease progression in idiopathic pulmonary fibrosis (IPF) and other ILDs. At the cellular level, these remodeling processes ultimately lead to the decline in lung function seen in patients.

For drug developers, this means that modifying ECM remodeling is a key therapeutic objective.

But to evaluate whether novel compounds are working, we need reliable tools that measure the biological processes driving the disease.

We have developed a panel of ECM remodeling biomarkers based on our ProteinFingerprint Technology™ and 30 years of biomarker expertise.

This panel enables:

• Assessment of disease activity
• Patient prognosis insights
• Measurement of pharmacodynamic responses
• Understanding of mechanisms of action

All biomarker analyses are performed in our CAP/CLIA-certified clinical laboratory, ensuring high-quality data for drug development programs.

We can also integrate standardized biomarkers, such as SP-D, to provide a comprehensive biomarker package for IPF studies.

If you’re working on IPF or ILD drug development, we’d be happy to discuss how ECM biomarkers can support your program.